This information was published on 2022-02-10T04:19:40 for IP Right Filed Published.
| Field | Value |
| (210) | 2248302 (IR 1644188) |
| (220) |
28 Dec 2021
|
| (300) |
US, 02 Jul 2021, 90808332
|
| (511) (510) |
Class 5
Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations. |
| (540) | RETRIG |
| (550) | Word |
| (730) |
PhaseBio Pharmaceuticals, Inc.
|
Find out more about publications on the About page.